Valdoxan is effective whatever the intensity of depressive symptoms. The efficacy of Valdoxan was observed in the more severely depressed patients (baseline HAM-D ≥ 25) in all positive placebo-controlled studies.

Efficacy of Valdoxan in severe depression

Results of the meta-analysis of three positive, randomized, double-blind, placebo controlled studies in 357 patients treated with Valdoxan and 360 patients treated with placebo show that Valdoxan is effective in treating severe depression. In the subgroup of severely depressed patients (defined as HAMD17 ≥ 25 at inclusion), Valdoxan was significant superior to placebo with a difference of 3 points on the HAMD17 scale after 6/8 weeks of treatment.

Valdoxan’s antidepressant effect is greater for more severe depression. In patients with a greater baseline score (>30 on HAMD17 scale), the Valdoxan-placebo difference was of 4.53 points.

Montgomery SA, Kasper S. Int Clin Psychopharmacol. 2007;22:283-291.

Efficacy on core symptoms